Evolution of CXCR4-using human immunodeficiency virus type 1 SF162 is associated with two unique envelope mutations

被引:13
作者
Kiselyeva, Yana
Nedellec, Rebecca
Ramos, Alejandra
Pastore, Cristina
Margolis, Leonid B.
Mosier, Donald E.
机构
[1] NICHD, Lab Mol & Cellular Biophys, NIH, Bethesda, MD 20892 USA
[2] Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA
关键词
D O I
10.1128/JVI.02310-06
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
CCR5-using human immunodeficiency virus type 1 (HIV-1) isolates typically gain CXCR4 use via multiple mutations in V3 and often V1/V2 regions of envelope, and patterns of mutations are distinct for each isolate. Here, we report that multiple CXCR4-using variants of a parental CCR5-using HIV-1 isolate, SF162, obtained by either target cell selection or CCR5 inhibition have a common mutation pattern characterized by the same two V3 mutations and that these mutations preexisted in some of the SF162 stocks. These results imply that SF162 has a single pathway for acquiring CXCR4 use and that prolonged culture is sufficient to select for R5X4 variants.
引用
收藏
页码:3657 / 3661
页数:5
相关论文
共 39 条
[1]   Adaptation to blockade of human immunodeficiency virus type 1 entry imposed by the anti-CCR5 monoclonal antibody 2D7 [J].
Aarons, EJ ;
Beddows, S ;
Willingham, T ;
Wu, LJ ;
Koup, RA .
VIROLOGY, 2001, 287 (02) :382-390
[2]   Codon and amino acid usage in retroviral genomes is consistent with virus-specific nucleotide pressure [J].
Berkhout, B ;
Grigoriev, A ;
Bakker, M ;
Lukashov, VV .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2002, 18 (02) :133-141
[3]   Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies [J].
Binley, JA ;
Wrin, T ;
Korber, B ;
Zwick, MB ;
Wang, M ;
Chappey, C ;
Stiegler, G ;
Kunert, R ;
Zolla-Pazner, S ;
Katinger, H ;
Petropoulos, CJ ;
Burton, DR .
JOURNAL OF VIROLOGY, 2004, 78 (23) :13232-13252
[4]  
Bjorndal A, 1997, J VIROL, V71, P7478
[5]   A CROSS-SECTIONAL COMPARISON OF PERSONS WITH SYNCYTIUM-INDUCING AND NON-SYNCYTIUM-INDUCING HUMAN-IMMUNODEFICIENCY-VIRUS [J].
BOZZETTE, SA ;
MCCUTCHAN, JA ;
SPECTOR, SA ;
WRIGHT, B ;
RICHMAN, DD .
JOURNAL OF INFECTIOUS DISEASES, 1993, 168 (06) :1374-1379
[6]   Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals [J].
Brumme, ZL ;
Goodrich, J ;
Mayer, HB ;
Brumme, CJ ;
Henrick, BM ;
Wynhoven, B ;
Asselin, JJ ;
Cheung, PK ;
Hogg, RS ;
Montaner, JSG ;
Harrigan, PR .
JOURNAL OF INFECTIOUS DISEASES, 2005, 192 (03) :466-474
[7]   Cooperative effects of the human immunodeficiency virus type 1 envelope variable loops V1 and V3 in mediating infectivity for T cells [J].
Carrillo, A ;
Ratner, L .
JOURNAL OF VIROLOGY, 1996, 70 (02) :1310-1316
[8]   V3 recombinants indicate a central role for CCR5 as a coreceptor in tissue infection by human immunodeficiency virus type 1 [J].
Chan, SY ;
Speck, RF ;
Power, C ;
Gaffen, SL ;
Chesebro, B ;
Goldsmith, MA .
JOURNAL OF VIROLOGY, 1999, 73 (03) :2350-2358
[9]   VIRAL DETERMINANTS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 T-CELL OR MACROPHAGE TROPISM, CYTOPATHOGENICITY, AND CD4 ANTIGEN MODULATION [J].
CHENGMAYER, C ;
QUIROGA, M ;
TUNG, JW ;
DINA, D ;
LEVY, JA .
JOURNAL OF VIROLOGY, 1990, 64 (09) :4390-4398
[10]  
CHENGMAYER C, 1988, ANN NEUROL S, V23, P58